Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Conference Correspondent | December 16, 2020
The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%.
Conference Correspondent | December 16, 2020
The preliminary results of the phase 1b/2 CARTITUDE-1 study revealed that early, deep, and durable responses were demonstrated and that a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM was observed.
Conference Correspondent | December 16, 2020
The updated efficacy and safety data from the ANCHOR study of melflufen plus dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging efficacy that was well-tolerated.
Conference Correspondent | December 16, 2020
Daratumumab + pomalidomide and dexamethasone reduced the risk for disease progression and death without additional safety signals versus pomalidomide and dexamethasone alone for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor.
Conference Correspondent | December 16, 2020
Talquetamab, a first-in-class bispecific antibody, showed encouraging efficacy with manageable toxicity in heavily pretreated patients with RRMM. An ongoing phase 2 investigation will determine the optimal dosing.
Conference Correspondent | December 16, 2020
Results from a phase 2 study of isatuximab in previously treated patients with amyloid light-chain (AL) amyloidosis showed encouraging efficacy and a good safety profile.
Conference Correspondent | December 16, 2020
Updated efficacy and safety results of the phase 2 GRIFFIN study (NCT02874742) in patients with transplant-eligible, newly diagnosed multiple myeloma who received daratumumab plus lenalidomide, bortezomib, and dexamethasone.
Conference Correspondent | December 16, 2020
The combination of selinexor, pomalidomide, and dexamethasone is efficacious, durable and safe in patients with RRMM.

Although the American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually because of the COVID-19 pandemic, hundreds of abstracts, posters, and presentations were still made available to inform clinicians on the latest developments in the treatment of lung cancer. This publication features some of the key highlights from the meeting, which can be used to improve the management and care of patients with the disease.

Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.
Page 1 of 9
Results 1 - 10 of 82

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code